SRT1720 is a selective activator of human SIRT1 (EC1.5 = 0.16 μM) versus the closest sirtuin homologues, SIRT2 and SIRT3 (SIRT2: EC1.5 = 37 μM；SIRT3: EC1.5 > 300 μM).
IC50 Value: 0.16 μM(EC1.5 for SIRT1)
Target: SIRT1
SRT 1720 binds to the SIRT1 enzyme-peptide substrate complex at an allosteric site amino-terminal to the catalytic domain and lower the Michaelis constant for acetylated substrates. In diet-induced obese and genetically obese mice, SRT1720 improved insulin sensitivity, lower plasma glucose, and increase mitochondrial capacity. Thus, SRT1720 is a promising new therapeutic agent for treating diseases of ageing such as type 2 diabetes

AK-7  AK-7 is a selective and brain-permeable SIRT2 inhibitor; is neuroprotective in Huntington disease mouse models.

IC50 value:
Target: SIRT2
AK-7 treated R6/2 mice performed significantly better than vehicle treated littermates on the accelerating rotarod at 8 and 11 weeks of age. AK-7 at the 10mg/kg dose was also effective in extending the survival of R6/2 mice. Mean survival of placebo treated R6/2 mice was 94.8±5.4, as compared with 109.2± 2.6 in AK-7 treated (10mg/kg) mice; mean survival of treated R6/2 mice was increased by 13.2%. At the 20 mg/kg dose, treatment with AK-7 caused a non-significant trend towards survival extension. No effect of the 30mg/kg dose on survival was observed, possibly due to systemic toxicity at this high dose.